Posted by Michael Wonder on 19 Feb 2026
Pilatus Biosciences receives FDA fast track designation for metabolic checkpoint inhibitor PLT012 in hepatocellular carcinoma
19 February 2026 - Pilatus Biosciences today announced that the US FDA has granted fast track designation for PLT012, the company’s first in class anti-CD36 monoclonal antibody for the treatment of hepatocellular carcinoma.
Pilatus is also developing PLT012 in additional solid tumour indications.
